Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cure51
Paris, Île-de-France, Francecure51.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Cure51 has launched the Rosalind study, collecting tumor samples from over 1,000 long-term survivors of aggressive cancers to build a unique multiomics database. The goal is to discover new biological mechanisms and targets for first-in-class oncology drugs. No clinical results have been reported yet as programs are in preclinical/target identification stages
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeBiologic
- Industry
- Drug Discovery Services
02
Partnerships
Gustave Roussy Cancer Campus (IGR, Paris)Leon Bérard Center (CLB, Lyon)Charité Universitätsmedizin BerlinIstituto Europeo di Oncologia MilanCambridge University Hospitalsseven other leading UK oncology institutions
Beyond the preview
Go deeper on Cure51.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cure51.